A point-of-research decision in synovial tissue engineering: Mesenchymal stromal cells, tissue derived fibroblast or CTGF-mediated mesenchymal-to-fibroblast transition DOI Creative Commons
Alexandra Damerau, Marieluise Kirchner, Philipp Mertins

et al.

European Journal of Cell Biology, Journal Year: 2024, Volume and Issue: 103(4), P. 151455 - 151455

Published: Sept. 10, 2024

Language: Английский

Exosomes in cartilage microenvironment regulation and cartilage repair DOI Creative Commons
Longfei Han,

Hou Wenyuan,

Weihua Fang

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13

Published: March 5, 2025

Osteoarthritis (OA) is a debilitating disease that predominantly impacts the hip, hand, and knee joints. Its pathology defined by progressive degradation of articular cartilage, formation bone spurs, synovial inflammation, resulting in pain, joint function limitations, substantial societal familial burdens. Current treatment strategies primarily target pain alleviation, yet improved interventions addressing underlying are scarce. Recently, exosomes have emerged as subject growing interest OA therapy. Numerous studies investigated to offer promising therapeutic approaches for through diverse vivo vitro models, elucidating mechanisms which from various cell sources modulate cartilage microenvironment promote repair. Preclinical investigations demonstrated regulatory effects originating human cells, including mesenchymal stem cells (MSC), fibroblasts, chondrocytes, macrophages, derived Chinese herbal medicines, on modulation repair signaling pathways. Additionally, encompass matrix, proliferation migration autophagy, apoptosis, mitigation oxidative stress. An increasing number exosome carrier scaffolds under development. Our review adopts multidimensional approach enhance comprehension pivotal functions exerted sourced types OA. Ultimately, our aim pinpoint targets capable regulating facilitating

Language: Английский

Citations

0
Shear Wave Elastography Reveals Elevated Infrapatellar Fat Pad Stiffness in Patients with Early Osteoarthritis Symptoms after ACL Reconstruction DOI Creative Commons
Matthew S. Harkey, Corey Grozier,

Jessica Tolzman

et al.

Osteoarthritis Imaging, Journal Year: 2025, Volume and Issue: unknown, P. 100267 - 100267

Published: March 1, 2025

Language: Английский

Citations

0
Intelligent Manufacturing for Osteoarthritis Organoids DOI Creative Commons
Xin Lyu, Jian Wang, Jiacan Su

et al.

Cell Proliferation, Journal Year: 2025, Volume and Issue: unknown

Published: April 26, 2025

ABSTRACT Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide, imposing a substantial global burden. However, its pathogenesis remains incompletely understood, and effective treatment strategies are still lacking. Organoid technology, in which stem cells or progenitor self‐organise into miniature tissue structures under three‐dimensional (3D) culture conditions, provides promising vitro platform for simulating pathological microenvironment of OA. This approach can be employed to investigate mechanisms, carry out high‐throughput drug screening facilitate personalised therapies. review summarises structure, OA manifestations, thereby establishing context application organoid technology. It then examines components arthrosis system, specifically addressing cartilage, subchondral bone, synovium, skeletal muscle ligament organoids. Furthermore, it details various constructing organoids, including considerations cell selection, classification fabrication techniques. Notably, this introduces concept intelligent manufacturing organoids by incorporating emerging engineering technologies such as artificial intelligence (AI) process, forming an innovative software hardware cluster. Lastly, discusses challenges currently facing highlights future directions rapidly evolving field. By offering comprehensive overview state‐of‐the‐art methodologies challenges, anticipates that intelligent, automated will expedite fundamental research, discovery translational applications orthopaedic

Language: Английский

Citations

0
Cytological taxonomy of chronic pain in rheumatoid arthritis: A brief descriptive review DOI Creative Commons
А. Е. Каратеев, Е. Yu. Polishchuk

Rheumatology Science and Practice, Journal Year: 2025, Volume and Issue: 63(2), P. 138 - 145

Published: May 1, 2025

Chronic pain is the main manifestation of rheumatoid arthritis (RA), determining severity suffering and functional impairment. Although in RA primarily associated with autoimmune inflammation, it can persist against background low activity even remission disease. This makes necessary to search for causes peculiarities development chronic RA. It seems that classification types help personalizing approaches its medication control. In this regard, evaluation relationship between cellular composition (pathotype) synovitis great interest. Three pathotypes are known: lymphoid (with predominance T B lymphocytes, plasmocytes), myeloid or diffuse-myeloid macrophages, monocytes, granulocytes) pauci-immune (mainly consisting fibroblast-like synoviocytes (FLS)). The pathotype characterised by high positivity factor anti-citrullinated protein antibodies, severe intense pain, including polyneuropathy dysfunctional disorders; characterized less local nociceptive pain; moderately peripheral hyperalgesia a moderate/low disease activity. last determine seronegative at late stages disease, which marked structural changes noted. Currently, there no clear view on drug different There limited evidence use CD20 inhibitors (rituximab) interleukin (IL) 6 pathotype, IL-6 tumour necrosis α pathotype. active drugs target FLS underway. data some studies indicate higher efficacy

Language: Английский

Citations

0
Edge advances in nanodrug therapies for osteoarthritis treatment DOI Creative Commons
Jinfeng Liao, Qinxuan Gu,

Zheng Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 30, 2024

As global population and lifestyles change, osteoarthritis (OA) is becoming a major healthcare challenge world. OA, chronic condition characterized by inflammatory degeneration, often present with joint pain can lead to irreversible disability. While there currently no cure for it commonly managed using nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, glucosamine. Although these treatments alleviate symptoms, difficult effectively deliver sustain therapeutic agents within joints. The emergence of nanotechnology, particularly in form smart nanomedicine, has introduced innovative approaches OA treatment. Nanotherapeutic strategies offer promising advantages, including more precise targeting affected areas, prolonged effects, enhanced bioavailability, reduced systemic toxicity compared traditional treatments. nanoparticles show potential as viable delivery system therapies based on encouraging lab-based clinical trials results, remails considerable gap between current research application. This review highlights recent advances nanotherapy explore future pathways refine optimize strategies.

Language: Английский

Citations

1
IL-17A exacerbates synovial inflammation in osteoarthritis via activation of endoplasmic reticulum stress DOI

Wen Sun,

Xueyan Li, Liyuan Zhang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 145, P. 113733 - 113733

Published: Dec. 10, 2024

Language: Английский

Citations

1
A point-of-research decision in synovial tissue engineering: Mesenchymal stromal cells, tissue derived fibroblast or CTGF-mediated mesenchymal-to-fibroblast transition DOI Creative Commons
Alexandra Damerau, Marieluise Kirchner, Philipp Mertins

et al.

European Journal of Cell Biology, Journal Year: 2024, Volume and Issue: 103(4), P. 151455 - 151455

Published: Sept. 10, 2024

Language: Английский

Citations

0